Key Players and Competitive Overview in the Cell and Gene Therapy Manufacturing Services Market

The cell and gene therapy manufacturing services sector is on the cusp of remarkable expansion, driven by innovations and increasing demand for advanced therapies. With the rise of personalized medicine and growing industry investments, this market is set to witness substantial growth in the coming years. Let's delve into the market size projections, key players, emerging trends, and segment breakdowns that define this evolving industry.

Projected Growth and Market Size of the Cell and Gene Therapy Manufacturing Services Industry
The market for cell and gene therapy manufacturing services is expected to grow rapidly, reaching a valuation of $21.05 billion by 2030. This expansion corresponds to a compound annual growth rate of 17.4%. Several factors contribute to this robust growth forecast, including the commercialization of cell and gene therapies, the increasing need for large-scale manufacturing solutions, the broadening of personalized medicine pipelines, improved regulatory clarity tailored for advanced therapies, and rising investments in the infrastructure needed to support these complex processes. Noteworthy trends shaping the market during this period include the expansion of GMP-compliant manufacturing facilities, wider adoption of automated cell processing technologies, a growing demand for scalable viral vector production, greater integration of cutting-edge quality control techniques, and a stronger focus on standardizing manufacturing protocols.

Download a free sample of the cell & gene therapy manufacturing services market report:
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Factors Propelling the Cell and Gene Therapy Manufacturing Services Market
The rapid commercialization of innovative cell and gene therapies is a major driver behind the increasing demand for specialized manufacturing services. These therapies require sophisticated production capabilities to ensure quality, safety, and scalability, fueling investments in state-of-the-art manufacturing infrastructure.
Additionally, the expanding pipeline of personalized medicines calls for flexible and efficient manufacturing processes that can handle diverse treatment modalities. Clearer regulatory frameworks are also encouraging companies to accelerate development efforts, further boosting the demand for manufacturing services tailored to advanced therapies.

Prominent Companies Leading the Cell and Gene Therapy Manufacturing Services Industry
The competitive landscape in this sector features a range of influential players, including Thermo Fisher Scientific Inc., Merck KGaA, Charles River Laboratories International Inc., Lonza Group AG, Catalent Inc., WuXi AppTec, Takara Bio Inc., Fujifilm Holdings Corporation, Oxford Biomedica plc, Cell and Gene Therapy Catapult, Samsung Biologics Co. Ltd., BioNTech SE, Novartis International AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Sarepta Therapeutics Inc., bluebird bio Inc., Precision BioSciences Inc., GSK plc, AstraZeneca plc, and Bayer AG.
A recent strategic move in June 2024 saw US-based Genezen acquire UniQure, a Netherlands-based biotech firm specializing in gene therapies for serious diseases. This acquisition aims to strengthen Genezen's gene therapy manufacturing capabilities and expand its service offerings, positioning the company to capitalize on the rising demand for innovative gene therapies worldwide.

The cell and gene therapy manufacturing services sector is on the cusp of remarkable expansion, driven by innovations and increasing demand for advanced therapies. With the rise of personalized medicine and growing industry investments, this market is set to witness substantial growth in the coming years. Let's delve into the market size projections, key players, emerging trends, and segment breakdowns that define this evolving industry.

Projected Growth and Market Size of the Cell and Gene Therapy Manufacturing Services Industry
The market for cell and gene therapy manufacturing services is expected to grow rapidly, reaching a valuation of $21.05 billion by 2030. This expansion corresponds to a compound annual growth rate of 17.4%. Several factors contribute to this robust growth forecast, including the commercialization of cell and gene therapies, the increasing need for large-scale manufacturing solutions, the broadening of personalized medicine pipelines, improved regulatory clarity tailored for advanced therapies, and rising investments in the infrastructure needed to support these complex processes. Noteworthy trends shaping the market during this period include the expansion of GMP-compliant manufacturing facilities, wider adoption of automated cell processing technologies, a growing demand for scalable viral vector production, greater integration of cutting-edge quality control techniques, and a stronger focus on standardizing manufacturing protocols.

Download a free sample of the cell & gene therapy manufacturing services market report:
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
Key Factors Propelling the Cell and Gene Therapy Manufacturing Services Market
The rapid commercialization of innovative cell and gene therapies is a major driver behind the increasing demand for specialized manufacturing services. These therapies require sophisticated production capabilities to ensure quality, safety, and scalability, fueling investments in state-of-the-art manufacturing infrastructure.
Additionally, the expanding pipeline of personalized medicines calls for flexible and efficient manufacturing processes that can handle diverse treatment modalities. Clearer regulatory frameworks are also encouraging companies to accelerate development efforts, further boosting the demand for manufacturing services tailored to advanced therapies.

Prominent Companies Leading the Cell and Gene Therapy Manufacturing Services Industry
The competitive landscape in this sector features a range of influential players, including Thermo Fisher Scientific Inc., Merck KGaA, Charles River Laboratories International Inc., Lonza Group AG, Catalent Inc., WuXi AppTec, Takara Bio Inc., Fujifilm Holdings Corporation, Oxford Biomedica plc, Cell and Gene Therapy Catapult, Samsung Biologics Co. Ltd., BioNTech SE, Novartis International AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Sarepta Therapeutics Inc., bluebird bio Inc., Precision BioSciences Inc., GSK plc, AstraZeneca plc, and Bayer AG.
A recent strategic move in June 2024 saw US-based Genezen acquire UniQure, a Netherlands-based biotech firm specializing in gene therapies for serious diseases. This acquisition aims to strengthen Genezen's gene therapy manufacturing capabilities and expand its service offerings, positioning the company to capitalize on the rising demand for innovative gene therapies worldwide.

Emerging Innovations and Market Trends in Cell and Gene Therapy Manufacturing
Leading firms in the sector are focusing on expanding GMP-compliant manufacturing capacities to meet the growing production needs of cell and gene therapies. This expansion is crucial to support the shift from development to commercial-scale manufacturing.
Moreover, the adoption of automated cell processing systems is growing, enhancing precision and efficiency while reducing human error. Increasing demand for scalable viral vector production also highlights the need for flexible, high-volume manufacturing solutions capable of supporting diverse therapeutic applications.

Detailed Segmentation of the Cell and Gene Therapy Manufacturing Services Market
This report outlines the cell and gene therapy manufacturing services market through several key segmented categories:
1) By Type: Gene Therapy and Cell Therapy
2) By Indication: Central Nervous System Disorders, Ophthalmology Diseases, Cardiovascular Diseases, Infectious Diseases, Orthopedic Diseases, and Oncology Diseases
3) By Application: Commercial Manufacturing and Clinical Manufacturing
4) By End-user: Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, and Other End-Users
Further subcategories include:
- For Gene Therapy: Viral Vector Manufacturing, Plasmid DNA Production, Gene Editing Services, and Formulation and Fill-Finish Services
- For Cell Therapy: Cell Sourcing and Banking, Cell Processing and Expansion, Quality Control and Testing Services, and Cryopreservation and Storage Services

These segments provide a comprehensive view of the industry's scope, highlighting the diverse areas where manufacturing services are critical to supporting the development and delivery of advanced therapies.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.